Features of the pharmacological actions and the use of dipyridamole in the prevention and treatment of viral infections

Cover Page
  • Authors: Kareva E.N1,2
  • Affiliations:
    1. N.I.Pirogov Russian National Research Medical University of the Ministry of Health of the Russian Federation
    2. I.M.Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation
  • Issue: Vol 18, No 12 (2016)
  • Pages: 80-87
  • Section: Articles
  • URL: https://journals.rcsi.science/2075-1753/article/view/94614
  • ID: 94614

Cite item

Full Text

Abstract

The review presents recent data on the molecular mechanisms of antiplatelet, vasodilatory, angioprotective, antifibrotic and immunomodulatory effects of dipyridamole. The data of national studies on testing the effectiveness and safety of dipyridamole (Curantyl) in the prevention of acute respiratory viral infections and in the treatment of recurrent stress-induced opportunistic infections, which have shown that dipyridamole is an effective drug complex action with a good safety profile and the ability to have a positive effect on vessels in metabolic disorders in patients with a history of history, enables effective prevention of acute respiratory viral infections in patients at high risk.

About the authors

E. N Kareva

N.I.Pirogov Russian National Research Medical University of the Ministry of Health of the Russian Federation; I.M.Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation

Email: elenakareva@mail.ru
д-р мед. наук, проф., каф. молекулярной фармакологии и радиобиологии ФГБОУ ВО РНИМУ им. Н.И.Пирогова, каф. фармакологии ЛФ ФГБОУ ВО Первый МГМУ им. И.М.Сеченова 117997, Russian Federation, Moscow, ul. Ostrovitianova, d. 1; 119991, Russian Federation, Moscow, ul. Trubetskaia, d. 8, str. 2

References

  1. Ahn H.S, Crim W, Romano M et al. Effects of selective inhibitors on cyclic nucleotide phosphodiesterases of rabbit aorta. Biochem Pharmacol 1989; 38: 3331-9.
  2. Aktas B, Utz A, Hoenig-Liedl P et al. Dipyridamole enhances NO/cGMP-mediated vasodilator - stimulated phosphoprotein phosphorylation and signaling in human platelets: in vitro and in vivo/ex vivo studies. Stroke 2003; 34 (3): 764-9.
  3. Balakumar P, Nyoa Y.H, Renushiaa R et al. Classical and pleiotropic actions of dipyridamole: Not enough light toilluminate the dark tunnel? Pharmacol Res 2014; 87: 144-50. doi: 10.1016/j.phrs.2014.05.008.
  4. Balakumar P, Varatharajan R, Nyo Y.H et al. Fenofibrate and dipyridamole treatments in low -doses either alone or in combination blunted the development of nephropathy in diabetic rats. Pharmacol Res 2014; 90: 36-47. doi: 10.1016/j.phrs.2014.08.008.
  5. Barzegar A. Proton - Coupled Electron - Transfer Mechanism for the Radical Scavenging Activity of Cardiovascular Drug Dipyridamole. PLoS ONE 2012; 7 (6): e39660. doi: 10.1371/journal.pone.0039660
  6. Ciacciarelli M, Zerbinati C, Violi F, Iuliano L. Dipyridamole: a drug with unrecognized antioxidant activity. Curr Top Med Chem 2015; 15 (9): 822-9.
  7. Costantini V, Talpacci A, Bastiano M.L et al. Increased prostacyclin production from human veins by dipyridamole: an in vitro and ex vivo study. Biomed Biochim Acta 1990; 49: 263-71.
  8. Della Corte G, Galasso F et al. Combinazione interferone a-2a per via sistemica e diatermocoagulazione versus semplice diatermocoagulazione nel trattamento dei condilomi acuminati. G Ital Dermatol Venereol 1992; 127: 309-13.
  9. Ernens I, Léonard F, Vausort M et al. Adenosine up - regulates vascular endothelial growth factor in human macrophages. Biochem Biophys Res Commun 2010; 392 (3): 351-6. doi: 10.1016/j.bbrc.2010.01.023.
  10. Ferrandon P, Barcelo B, Perche J.C, Schoffs A.R. Effects of dipyridamole, soluflazine and related molecules on adenosine uptake and metabolism by isolated human red blood cells. Fundam Clin Pharmacol 1994; 8: 446-52.
  11. Francis S.H, Blount M.A, Corbin J.D. Mammalian Cyclic Nucleotide Phosphodiesterases: Molecular Mechanisms and Physiological Functions. Physiol Rev 2011; 91: 651-90. doi: 10.1152/physrev.00030.2010.
  12. Galabov A.S, Mastikova M. Acta Virol 1982; 38: 137-47.
  13. Galabov A.S, Mastikova M. Dipyridamole induces interferon in man. Biomed Pharmacother 1984; 38: 412-3.
  14. Galabov A.S, Mastikova M. Interferon - inducing activity of dipyridamole in mice. Acta Virologica Prague 1983; 27: 356-8.
  15. Geiger J, Nolte C, Walter U. Regulation of calcium mobilization and entry in human platelets by endothelium - derived factors. Am J Physiol 1994; 267: C236-C244.
  16. Gresele P, Arnout J, Deckmyn H, Vermylen J. Mechanism of the antiplatelet action of dipyridamole in whole blood: modulation of adenosine concentration and activity. Thromb Haemost 1986; 55: 12-8.
  17. Goda A.E, Yoshida T, Horinaka M et al. Mechanisms of enhancement of TRAIL tumoricidal activity against human cancer cells of different origin by dipyridamole. Oncogene 2008; 27: 3435-45. doi: 10.1038/sj.onc.1211008.
  18. Guo Sh, Stins M, Ning M.M, Lo E.H. Amelioration of Inflammation and Cytotoxicity by Dipyridamole in Brain Endothelial Cells. Cerebrovasc Dis 2010; 30: 290-6. doi: 10.1159/000319072.
  19. Hsieh M.S, Zhong W.B, Yu S.C et al. Dipyridamole suppresseshigh glucose - induced osteopontin secretion and mRNA expression in rat aorticsmooth muscle cells. Circ J 2010; 74: 1242-50.
  20. Hung K-Y, Chen C-T, Yen C-J et al. Dipyridamole inhibits PDGF-stimulated human peritoneal mesothelial cell proliferation. Kidney International 2001; 60: 872-81.
  21. Jefferson T.O, Tyrrel D. Antivirals for the common cold. The Cochrane Database of Systematic Reviews, Issue. Art. No.: CD002743. doi: 10.1002/14651858. CD002743, 2004.
  22. Kam A, Razmovski-Naumovski V, Xian Zhoub et al. Nucleoside Transport Inhibition by Dipyridamole Prevents Angiogenesis Impairment by Homocysteine and Adenosine. J Pharm Pharm Sci 2015; 18 (5): 871-81.
  23. Kim H-H, James K. Liao Translational Therapeutics of Dipyridamole. Arterioscler Thromb Vasc Biol 2008; 28: s39-s42.
  24. Kim J.A, Tran N.D, Zhou W, Fisher M. Dipyridamole enhances tissue plasminogen activator release by brain capillary endothelial cells. Thromb Res 2005; 115 (5): 435-8.
  25. Kyttaris V.C, Zhang Zh, Kampagianni O, Tsokos G.C. Calcium Signaling in Systemic Lupus Erythematosus T Cells A Treatment Target. Arthritis Rheum 2011; 63 (7): 2058-66. doi: 10.1002/art.30353.
  26. Lana D, Melani A, Pugliese A.M et al. The neuron - astrocyte - microglia triad in a rat model of chronic cerebral hypoperfusion: protective effect of dipyridamole. Front Aging Neurosci 2014; 27 November. http://dx.doi.org/10.3389/fnagi.2014.00322
  27. Lenz T.L, Hilleman D.E. Aggrenox: a fixed - dose combination of aspirin and dipyridamole. Ann Pharmacother 2000; 34 (11): 1283-90.
  28. Massaro M, Scoditti E, Carluccio M.A et al. Dipyridamole decreases inflammatory metalloproteinase-9 expressionand release by human monocytes. Thromb Haemost 2013; 109: 280-9.
  29. Pattillo Ch.B, Fang K, Terracciano J, Kevil C.G. Reperfusion of chronic tissue ischemia: nitrite and dipyridamole regulation of innate immune responses. Ann N Y Acad Sci 2010; 1207: 83-8. doi: 10.1111/j.1749-6632.2010.05737.
  30. Pattillo Ch.B, Bir S.C, Branch B.G et al. Dipyridamole Reverses Peripheral Ischemia and Induces Angiogenesis in the Db/Db Diabetic Mouse Hind Limb Model by Decreasing Oxidative Stress. Free Radic Biol Med 2011; 50 (2): 262-9. doi: 10.1016/j.freeradbiomed.2010.10.714.
  31. Saino T, Misaki T, Matsuura M et al. Dipyridamole inhibits intracellular calcium transients in isolated rat arteriole smooth muscle cells. Arch Histol Cytol 2008; 71 (4): 235-47.
  32. Schaper W. Dipyridamole, an Underestimated Vascular Protective Drug. Cardiovasc Drugs Ther 2005; 19: 357-63.
  33. Schwarz U.R, Walter U, Eigenthaler M. Taming platelets with cyclic nucleotides. Biochem Pharmacol 2001; 62: 1153-61.
  34. Uchakin P.N, Surkina I.D, Gotovtseva E.P et al. J Interferon Res 1992; 12: 124.
  35. Wang Ch, Schwab L.P, Fan M et al. Chemoprevention Activity of Dipyridamole in the MMTV-PyMT Transgenic Mouse Model of Breast Cancer. Cancer Prev Res (Phila) 2013; 6 (5). doi: 10.1158/1940-6207.CAPR-12-0345.
  36. Wang C, Lin W, Playa H et al. Dipyridamole analogs as pharmacological inhibitors of equilibrative nucleoside transporters. Identification of novel potent and selective inhibitors of the adenosine transporter function of human equilibrative nucleoside transporter 4 (hENT4). Biochem Pharmacol 2013; 86: 1531-40.
  37. Weyrich A.S, Denis M.M, Kuhlmann-Eyre J.R et al. Dipyridamole Selectively Inhibits Inflammatory Gene Expression in Platelet-Monocyte Aggregates. Circulation 2005; 111: 633-42.
  38. Zhuplatov S.B, Masaki T, Blumenthal D.K, Cheung A.K. Mechanism of dipyri - damole’s action in inhibition of venous and arterial smooth muscle cellproliferation. Basic Clin Pharmacol Toxicol 2006; 99: 431-9.
  39. Барышникова Г.А. Дипиридамол в общетерапевтической практике. Проблемы женского здоровья. 2007; 2 (1).
  40. Григорян С.С., Поверенный А.М., Ершов Ф.И. Вазодилататоры как индукторы интерферона. Вопр. вирусологии. 1987; 3: 356-7.
  41. Григорян С.С. Индукторы интерферона: действие на интерфероновый статус в норме и при патологии. Автореф. дис. … д - ра мед. наук. М., 1992.
  42. Гуревич К.Г., Суркина И.Д., Готовцева Е.П. и др. Дипиридамол в лечении рецидивирующих стресс - индуцированных оппортунистических инфекционных заболеваний. Рус. мед. журн. 2000; 13: 554-6. http://www.rmj.ru/articles/infektsiya/Dipiridamol_v_lechenii_recidiviruyuschih_stress-inducirovannyh_opportunisticheskih_infekcionnyh_zabolevaniy/#ixzz4DT2Yx6cM
  43. Ершов Ф.И. В кн.: Система интерферона в норме и при патологии. M., 1996; с. 239.
  44. Ершов Ф.И., Григорян С.С. Курантил как средство неспецифической профилактики гриппа и других ОРВИ. Рекомендации для врачей. Петрозаводск: ИнтелТек, 2004.
  45. Кузмов К., Галабов А.С., Радова X. и др. Эпидемиологическое испытание профилактической эффективности индуктора интерферона дипиридамола в отношении острых респираторных заболеваний. Журн. микробиологии, эпидемиологии, иммунологии. 1985; 6: 26-30.
  46. Лукьянов С.В., Белоусов Ю.Б. В кн.: Клиническая фармакология курантила (дипиридамола). M., 1998.
  47. Меерсон Ф.З. В кн.: Адаптация, стресс, профилактика. M., 1981.
  48. Слепушкин А.Н., Федорова Г.И. Клиническое применение дипиридамола (Курантила) для профилактики острых респираторных заболеваний. Клин. фармакология и терапия. 2000; 9: 39-41.
  49. Суркина И.Д. Интерферон - индуцирующие эффекты дипиридамола: противовирусные и регуляторные. Терапевт. арх. 2000; 8: 61-4.
  50. Федоровская Е.О., Пелевина И.И., Ершов Ф.И., Григорян С.С. Подавление метастазирования карциномы Льюис у мышей вазодилататором курантилом, индуцирующим интерферон. БЭБиМ. 1989; 1: 83-5.
  51. Johnston-Cox H.A, Ravid K. Adenosine and blood platelets. Purinergic Signalling. 2011; 7: 357-65. doi: 10.1007/s11302-011-9220-4.

Copyright (c) 2016 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies